Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.

British Journal of Haematology

Volumn 106, Issue 1, 1999, Pages 47-54

  Sweetenham, John ^b   Hieke, Klaus ^a   Kerrigan, Matthew ^a   Howard, Paul ^c   Smartt, Pamela F M ^c   McIntyre, Ann Marie ^c   Townshend, Sarah ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c NONE

Author keywords

CHOP; Costs; Fludarabine; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; COST CONTROL; DRUG COST; FEVER; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; UNITED KINGDOM; VOMITING;

AMBULATORY CARE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LENGTH OF STAY; LYMPHOMA, B-CELL; MIDDLE AGED; PREDNISONE; RECURRENCE; RETROSPECTIVE STUDIES; VIDARABINE; VINCRISTINE;

EID: 0032838146     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01515.x     Document Type: Article

References (32)

1. Armitage, J.O. (1993) Treatment of non-Hodgkin's Lymphoma. Drug Therapy, 328, 1023-1030.
2. Bennett, C.L., Armitage, J.L., Armitage, G.O., Vose, J.M., Bierman, P.J., Armitage, J.O. & Anderson, J.R. (1995) Costs of care and outcomes for high dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. Journal of Clinical Oncology, 13, 969-973.
3. Bobey, N. & Woodman, R.C. (1998) Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF). Clinics in Investigative Medicine, 21, (2), 63-70.
4. Craig, A.-M., Malek, M., Davey, P. & Szucs, T. (1996) Economic evaluation with decision analysis: is it useful for medical decision making? The case of acute uncomplicated cystitis in women. British Journal of Medical Economics, 10, 275-290.
5. Dranitsaris, G. & Sutcliffe, S.B. (1995) Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma. Leukemia and Lymphoma, 17, 139-145.
6. Falkson, C.I. (1996) Fludarabine: a phase II trial in patients with previously low-grade lymphoma. American Journal of Clinical Oncology, 19, 268-270.
7. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A. & Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002-1006.
8. Foran, J.M. Rohatiner, A.Z.S., Cunningham, D.C., Popescu, R., Goldstone, A.H., Sweetenham, J.W., Johnson, P., Sessell, E., Pettengell, R., Hancock, B. & Lister, T.A. (1998a) Immunotherapy of recurrent follicular lymphoma (FL) with rituximab (IDEC-C2B8): preliminary results of an ongoing UK multicentre trial. (Abstract). British Journal of Haematology, 102, 969.
9. Foran, J.M., Rohatiner, A.Z.S., Cunningham, D.C., Popescu, R., Solal-Celigny, P., Cavalli, F., Coiffier, B., Johnson, P., Gisselbrecht, C., Haioun, C., Bessell, E., Sweetenham, J., Radford, J., Benzohra, A. & Lister, T.A. (1998b) Immunotherapy of mantle cell lymphoma, lymphoplasmacytoid lymphoma, Walderstron's macroglobulinaemia, and small lymphocytic lymphoma with rituximab (IDEC-C2B8): preliminary results of an international multicentre trial. (Abstract). British Journal of Haematology, 102, 586.
10. Hancock, B.W. & Baber, A. (1995) The cost-effectiveness of cancer chemotherapy: a clinician's view. Proceedings of the Royal College of Physicians of Edinburgh, 25, 61-66.
11. Hochster, H.S., Kim, K., Green, M.D., Mann, R.B., Neiman, R.S., Oken, M.M., Cassileth, P.A., Stott, P., Ritch, P. & O'Connell, M.J. (1992) Activity of fludarabine in previously treated non-Hodgkin's lymphoma: results of an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology, 10, 28-32.
12. Johnson, P.Q.M., Rohatiner, A.Z.S., Whelan, J.S., Price, C.G.A., Love, S., Lim, J., Matthews, J., Norton, A.J., Amess, J.A.L. & Lister, T.A. (1995) Patterns of survival in patients with recurrent follicular lymphoma: a 20 year study from a single centre. Journal of Clinical Oncology, 13, 140-147.
13. Kimby, E., Bjorkholm, M., Gahrton, G., Glimelius, B., Hagberg, H., Johansson, B., Johansson, H., Juliusson, G., Jarnmark, M., Lofvenberg, E., Killander, A., Lerner, R., Lindemalm, C., Pettersson, U., Robert, K.-H., Simonsson, B., Stalfelt, A.-M., Sundstrom, C., Svedmyr, E., Uden, A.-M., Wadman, B., Wahlin, A. & Ost, A. (1944) Chlorambucil/prednisone vs CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomised trial from the Lymphoma Group of Central Sweden. Annals of Oncology, 5, (Suppl. 2), S67-S71.
14. Maloney, D.G., Grillo-Lopez, A.J., White, C., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.-M., Dallaire, B.K., Wey, K., Royston, I., Davis, T. & Levy, R. (1997) IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, 2188-2195.
15. McLaughlin, P., Grillo-López, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
16. Miller, T.P., Dahlberg, S., Cassady, R., Adelstein, D.J., Spier, C.M., Grogan, T.M., LeBlanc, M., Carlin, S., Chase, E. & Fisher, R.I. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. New England Journal of Medicine, 339, 21-26.
17. Pigaditou, A., Rohatiner, A.Z.S., Whelan, J.S., Johnson, P.W.M., Ganjoo, R.K., Rossi, A., Norton, A.J.A., Amess, J., Lim, J. & Lister, T.A. (1993) Fludarabine in low grade lymphoma. Seminars in Oncology, 20, (Suppl. 7), 24-27.
18. Portlock, C.S. (1990) Management of the low-grade non-Hodgkin's lymphomas. Seminars in Oncology, 17, 51-59.
19. Smith, T.J., Hillner, B.E., Schmitz, N., Linch, D.C., Dreger, P., Goldstone, A.H., Boogaerts, M.A., Ferrant, A., Link, H., Zander, A., Yanovich, S., Kitchin, R. & Erder, M.H. (1997) Economic analysis of a randomized clinical trial to compare filgrastimmobilized peripheral-blood progenitor-call transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. Journal of Clinical Oncology, 15, 5-10.
20. Solal-Celigny, P., Brice, P., Brousse, H., Caspard, H., Bastion, Y., Haioun, C., Bosly, A., Tilly, H., Bordessoule, D., Sebban, C., Harousseau, J.L., Morel, P., Dupas, B., Plassart, F., Vasile, N., Fort, N. & Leporrier, M. (1996) Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 14, 514-519.
21. Spinolo, J.A., Cabanillas, F., Dixon, D.O., Khorana, S.M., McLaughlin, P., Velasquez, W.S., Hagemeister, F.B., Redman, J.R. & Swan, F., Jr (1992) Therapy of relapsed or refractory low grade follicular lymphomas: factors associated with complete remission, survival and time to treatment failure. Annals of Oncology, 3, 227-232.
22. Tarella, C., Castellino, C., Locatelli, F., Caracciolo, D., Corradini, P., Falda, M., Novarino, A., Tasi, V. & Pileri, A. (1998) G-CSF administration following peripheral blond progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplantation, 21, 401-407.
23. Tolley, K., Morgan, G., Cartwright, R. & Williams, R. (1998) Economic aspects of non-Hodgkin's lymphoma. Office of Health Economics, Paper No. 123.
24. Uyl-de Groot, C.A., Hagenbeek, A., Verdonck, L.F., Lowenberg, B. & Rutten, F.F. (1995a) Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate and high grade malignant non-Hodgkin's lymphoma. Bone Marrow Transplantation, 16, 463-470.
25. Uyl-de Groot, C.A., Okhuijsen S.Y., Hagenbeek, A., Huijgens, P.C., van Imhoff, G.W., Lowenberg, B., Verdonck, L.F. & Rutten, F.F. (1995b) Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplantation, 15, 605-610.
26. Vose, J.M. (1996) Classification and clinical course of low grade non-Hodgkin's lymphomas with overview of therapy. Annals of Oncology, 7, (Suppl. 6), S13-S19.
27. Webster, K. & Cella, D. (1998) Quality of life in patients with low-grade non-Hodgkin's lymphoma. Oncology, 12, 697-714.
28. Weisenberger, D.D. (1992) Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Annals of Oncology, 5, (Suppl. 1), 19-24.
29. Whelan, J.S., Davis, C.L., Rule, S., Kanson, M., Smith, O.P., Mehta, A.B., Catovsky, D., Rohatiner, A.Z.S. & Lister, T.A. (1991) Fludarabine phosphate for the treatment of low grade lymphoid malignancy. British Journal of Cancer, 64, 120-123.
30. Woronoff-Lemsi, M.C., Arveux, P., Limat, S., Deconinck, E., Morel, P. & Cahn, J.Y. (1997) Cost comparative study of autologous peripheral progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. Bone Marrow Transplantation, 20, 975-982.
31. Young, R.C., Longo, D.L., Glatstein, E., Ihde, D.C., Jaffe, E.S. & De Vita, V.J. (1988) The treatment of indolent lymphomas: watchful waiting versus aggressive combined modality treatment. Seminars in Hematology, 25, 1-16.
32. Zinzani, P.L., Lauria, F., Rondelli, D., Benfenati, D., Raspadori, D., Bocchia, M., Bendandi, M., Gozzetti, A., Zaja, F., Fanin, R., Russo, D., Galieni, P. & Tura, S. (1993) Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Annals of Oncology, 4, 575-578.